期刊论文详细信息
Biomarkers in Cancer
The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy: Supplementary Issue: Biomarkers and their Essential Role in the Development of Personalised Therapies (A)
ChristineHenri1 
关键词: biomarkers;    cardiotoxicity;    cancer;    chemotherapy;    natriuretic peptides;    troponin;   
DOI  :  10.4137/BIC.S31798
学科分类:医学(综合)
来源: Sage Journals
PDF
【 摘 要 】

With the improvement of cancer therapy, survival related to malignancy has improved, but the prevalence of long-term cardiotoxicity has also increased. Cancer therapies with known cardiac toxicity include anthracyclines, biologic agents (trastuzumab), and multikinase inhibitors (sunitinib). The most frequent presentation of cardiac toxicity is dilated cardiomyopathy associated with poorest prognosis. Monitoring of cardiac toxicity is commonly performed by assessment of left ventricular (LV) ejection fraction, which requires a significant amount of myocardial damage to allow detection of cardiac toxicity. Accordingly, this creates the impetus to search for more sensitive and reproducible biomarkers of cardiac toxicity after cancer therapy. Different biomarkers have been proposed to that end, the most studied ones included troponin release resulting from cardiomyocyte damage and natriuretic peptides reflecting elevation in LV filling pressure and wall stress. Increase in the levels of troponin and natriuretic peptides have been correlated with cumulative dose of anthracycline and the degree of LV dysfunction. Troponin is recognized as a highly efficient predictor of early and chronic cardiac toxicity, but there remains some debate regarding the clinical usefulness of the measurement of natriuretic peptides because of divergent results. Preliminary data are available for other biomarkers targeting inflammation, endothelial dysfunction, myocardial ischemia, and neuregulin-1. The purpose of this article is to review the available data to determine the role of biomarkers in decreasing the risk of cardiac toxicity after cancer therapy.

【 授权许可】

CC BY   

【 预 览 】
附件列表
Files Size Format View
RO201901215967972ZK.pdf 293KB PDF download
  文献评价指标  
  下载次数:3次 浏览次数:10次